DLDenisa Lipcseyová

Denisa Lipcseyová

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denisa Lipcseyová has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Jan Benes

    Department of Cardiology, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic

    1 shared publication
  • Jiri Petrak

    First Faculty of Medicine (M.B., D.L., O.V., J.P.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic

    1 shared publication
  • Matej Behounek

    First Faculty of Medicine (M.B., D.L., O.V., J.P.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic

    1 shared publication
  • Ondřej Vít

    First Faculty of Medicine (M.B., D.L., O.V., J.P.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic

    1 shared publication
  • Pavel Talacko

    Proteomic Core Facility, Faculty of Science (P.Z., P.T.), Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic

    1 shared publication
  • Peter Wohlfahrt

    Department of Cardiology (T.T., P.W., V.M., J.B.), Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic

    1 shared publication

Latest Publications

  • Open Access

    Biomarkers of RV Dysfunction in HFrEF Identified by Direct Tissue Proteomics: Extracellular Proteins Fibromodulin and Fibulin-5

    by Matěj Běhounek, Denisa Lipcseyová, Ondřej Vít, Petr Žáček, Pavel Talacko, Zuzana Husková, Soňa Kikerlová, Tereza Tykvartová, Peter Wohlfahrt, Vojtěch Melenovský, et al.

    BACKGROUND: Right ventricular dysfunction (RVD) is common in patients with heart failure with reduced ejection fraction, and it is associated with poor prognosis. However, no biomarker reflecting RVD is available for routine clinical use. METHODS: Proteomic analysis of myocardium from the left ventricle and right ventricle (RV) of patients with heart failure with reduced ejection fraction with (n=10) and without RVD (n=10) who underwent heart transplantation was performed. Concentrations of 2 ECM (extracellular matrix) proteins with the highest myocardial upregulation in RVD, FMOD (fibromodulin) and FBLN5 (fibulin-5), were assayed in the blood and tested in a separate cohort of patients with heart failure with reduced ejection fraction (n=232) to test for the association of the 2 proteins with RV function and long-term outcomes. RESULTS: Multivariable linear regression revealed that plasma concentrations of both FMOD and FBLN5 were significantly associated with RV function regardless of the RV function assessment method. No association of FMOD or FBLN5 with left ventricular dysfunction, cardiac index, body mass index, diabetes status, or kidney function was found. Plasma levels of FMOD and FBLN5 were significantly associated with patient outcomes ( P =0.005; P =0.004). Area under the curve analysis showed that the addition of FBLN5 or FMOD to RV function assessment had a significantly higher area under the curve after 4 years of follow-up (0.653 and 0.631, respectively) compared with RV function alone (0.570; P 64 ng/mL and FMOD >27 ng/mL) had a worse prognosis than those with the elevation of either FBLN5 or FMOD ( P =0.03) demonstrating the additive prognostic value of both proteins. CONCLUSIONS: Our study proposes that circulating levels of FMOD and FBLN5 may serve as new biomarkers of RVD in patients with heart failure with reduced ejection fraction.